Phase 2 N=45 Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Discontinuations Due to Adverse Events (AE) — 1; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=70 Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder
Attention Deficit Hyperactivity Disorder · Substance Abuse
Primary: Change in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Attention-deficit/Hyperactivity Disorder (ADHD) Checklist — 18.61; 18.19 units on a…
Phase 2 N=20 Atomoxetine and Huntington's Disease
Huntington Disease · Chorea
Primary: Conners' Adult Attention Rating Scale (CAARS) — -2.88; -2.24 units on a scale — p=0.63
N/A N=42 Atomoxetine PBPK-PD Clinical Study
ADHD
Primary: Number of Participants Classified as Responders and Non-responders to Intervention — 14; 15 Participants
Phase 4 N=93 Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
Attention Deficit Disorder With Hyperactivity
Primary: Change in ADHD-IV Rating Scale Total Score — -13.2; -5.8 units on a scale
Phase 3 N=391 Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in the Conners' Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) 18-Item Total…
Phase 4 N=502 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline to 24 Weeks in the Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scale - Investigator Rated: Screening Version (CAARS-Inv:SV) Total…
Phase 2 N=38 Atomoxetine Treatment for ADHD and Marijuana Dependence
Marijuana Abuse · Attention Deficit Disorder With Hyperactivity
Primary: Estimated Week 12 Self-reported Use — 2.17; 1.84 Times per day
N/A N=18 Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Attention Deficit Hyperactivity Disorder
Primary: Change in Adult ADHD Investigator Symptom Rating Scale Score — 17.3 units on a scale
Phase 2 N=20 Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity · Cocaine-Related Disorders
Primary: the Adult ADHD Rating Scale (AARS) (30% Reduction) — 50 percent of participants
Phase 4 N=128 Atomoxetine, Placebo and Parent Management Training in Autism
Autism · Pervasive Development Disorder · Asperger's Disorder
Primary: Percentage of Participants Who Were Attention Deficit Hyperactivity Disorder (ADHD) Respondents — 45.2; 46.9; 29.0; 19.4 percentage of participants — p=0.47
Phase 3 N=153 Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline to Day 42 Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored…
Phase 4 N=97 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder
Autistic Disorder · Attention Deficit Disorder With Hyperactivity
Primary: ADHD Rating Scale-IV-Parent Version: Investigator Scored - Total Score — 40.7; 38.6; 32.3; 37.3 units on a scale — p=<0.001
Phase 2 N=30 Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)
Parkinson's Disease · Cognitive Impairment
Primary: The Global Statistical Test Combined Information on Change From Baseline on a Battery of Standardized Executive Function Tests — 99.5; 117.5 summed-ranks — p=0.25
Phase 2 N=39 Effects of Atomoxetine in Mild Cognitive Impairment
Mild Cognitive Impairment
Primary: Change in Interleukin 1 (IL 1-alpha) in Cerebrospinal Fluid (CSF) in Subjects With Mild Cognitive Impairment (MCI) Treated With Atomoxetine/Inactive Compound Compared to…
Phase 4 N=125 Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline Computer-based Continuous Performance Test (cb- CPT; Qbtech AB, Sweden), Variable: Hyperactivity (Includes Time Active [TA], Distance [DIS], Area…
Phase 2 N=45 Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Number of Participants With Adverse Events Leading to Discontinuation — 1; 1; 1 participants
Phase 3 N=1,553 Long-Term, Open Label Atomoxetine Study
Attention Deficit Hyperactivity Disorder
Primary: Categorical Changes in Vital Signs (Blood Pressure [BP], Pulse, Weight, Temperature) During the Study — 228; 92; 19; 39 participants
Phase 4 N=445 Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
Attention Deficit Hyperactivity Disorder
Primary: Mean Change in the Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version (CAARS-Inv:SV) Total ADHD Symptom Score From Baseline to 12 Week Endpoint…
Phase 3 N=399 A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline to 6 Month Endpoint in Child Health and Illness Profile - Child Edition, Parent Report Form (CHIP-CE PRF), Achievement Domain — 28.0; 28.3; 8.4…
Phase 2 N=50 Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial
Substance Abuse
Primary: % Urine Samples Negative for Cocaine — .67; .74 percentage of positive urine samples
Phase 2 N=13 Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Time Till Relapse — 7; -8 Days to Relapse — p=<0.05
Phase 4 N=44 Atomoxetine in Veterans With Comorbid ADHD/PTSD
Post Traumatic Stress Disorder · Attention Deficit Hyperactivity Disorder
Primary: Conners' Adult ADHD Rating Scales-Self-Report: Short Version (CAARS-S:S, Conner et al, 1999) — 75.12; 68.56; 67.79; 72.80 units on a scale
Phase 3 N=151 Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score at 12 Week Endpoint…
Phase 4 N=121 Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
Attention Deficit Hyperactivity Disorder · Reading Disorder
Primary: Stop Signal Reaction Time (SSRT) as Derived From the Stop Signal Reaction Time Paradigm — 299.90; 308.82; 265.61; 260.51 milliseconds (msec) — p=0.504
Phase 4 N=45 Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)
ADHD NOS
Primary: ADHD-Clinical Global Impression — 29 subjects
Phase 3 N=269 Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline to 12 Week Endpoint in Child Health and Illness Profile - Child Edition (CHIP-CE), Achievement Domain — 2.65; 0.51; 3.89 T-Score
Phase 3 N=60 Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
Autism
Primary: ADHD Rating Scale (ADHDRS)-Home Version Total Score (Randomized Phase) — 28.7; 34.0 units on a scale
Phase 3 N=228 Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)
Attention Deficit Hyperactivity Disorder
Primary: Number of Participants With Adverse Events for Long Term Safety and Tolerability — 6; 222 Participants
Phase 4 N=37 Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
Schizophrenia
Primary: Change From Baseline in Weight — 1.7; 2.1 kilograms